Clinical trials lie at the heart of MannKind’s pursuit to transform medical potential into tangible progress. Each trial illuminates the path toward more effective treatments and therapies. Through meticulous testing and observation, focused on ensuring safety, we uncover the insights that shape medical breakthroughs. At MannKind, our commitment to clinical trials echoes our commitment to humanity, as we work tirelessly to elevate healthcare standards and pave the way for a safer, healthier, and more equitable future.
INFLO-1 Phase 1b, is a randomized, double-blind, placebo-controlled study of Nintedanib DPI in patients with idiopathic pulmonary fibrosis (IPF). The trial consists of multiple ascending doses with the primary objective to evaluate safety, tolerability, and pharmacokinetics of Nintedanib DPI in patients with IPF.
Learn MoreINHALE-1st is a single-arm, multi-center, clinical study evaluating the safety and efficacy of inhaled insulin in combination with basal insulin (BI) for youth ages 10 to under 18 who have been newly diagnosed with stage 3 type 1 diabetes. The study will also look at how satisfied participants and their parents or legally authorized representatives are with using inhaled insulin plus BI as part of their treatment plan. All participants will use inhaled insulin + BI and will be followed for 13 weeks during the main phase of the study. Those who wish to continue may choose to enter an optional extension phase for up to an additional 26 weeks.
Learn MoreINHALE-1 is a Phase 3, randomized controlled trial in children and teenagers aged 4-17 with type 1 or type 2 diabetes to evaluate the efficacy and safety of inhaled insulin in combination with basal insulin (BI) versus multiple daily injections of rapid acting insulin in combination with BI.
Learn MoreCheck out our research and development pipeline focused on endocrine and orphan lung disease
explore our products and pipeline see products and pipelineSee how our technologies and therapies can help more people take control of their health.
view publications